CN116445346B - Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof - Google Patents
Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof Download PDFInfo
- Publication number
- CN116445346B CN116445346B CN202310399703.5A CN202310399703A CN116445346B CN 116445346 B CN116445346 B CN 116445346B CN 202310399703 A CN202310399703 A CN 202310399703A CN 116445346 B CN116445346 B CN 116445346B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- ovary syndrome
- polycystic ovary
- strain
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 73
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 52
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 50
- 238000004321 preservation Methods 0.000 claims abstract description 15
- 239000006041 probiotic Substances 0.000 claims description 32
- 235000018291 probiotics Nutrition 0.000 claims description 32
- 239000001963 growth medium Substances 0.000 claims description 28
- 241000186660 Lactobacillus Species 0.000 claims description 26
- 229940039696 lactobacillus Drugs 0.000 claims description 26
- 230000000529 probiotic effect Effects 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 10
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 10
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- -1 mannooligosaccharide Chemical compound 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 16
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 12
- 230000002503 metabolic effect Effects 0.000 abstract description 6
- 230000005856 abnormality Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 40
- 238000012360 testing method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000009630 liquid culture Methods 0.000 description 16
- 239000003833 bile salt Substances 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 210000004051 gastric juice Anatomy 0.000 description 8
- 208000030159 metabolic disease Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 7
- 229960003881 letrozole Drugs 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 150000004666 short chain fatty acids Chemical class 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004246 corpus luteum Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000004153 glucose metabolism Effects 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002068 microbial inoculum Substances 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- 238000003968 anodic stripping voltammetry Methods 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000007412 host metabolism Effects 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 241001622054 Lactobacillus reuteri ATCC 53608 Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to lactobacillus reuteri for improving polycystic ovary syndrome and application thereof, wherein the lactobacillus reuteri for improving polycystic ovary syndrome is named as lactobacillus reuteri Lactobacillus reuteri LR strain, the preservation number is CGMCC No.24408, and the preservation date is 2022, 02 and 21 days. The strain can effectively improve polycystic ovary syndrome and symptoms of related metabolic level disturbance and sex hormone level abnormality, and can be used for preparing products for preventing, relieving or treating polycystic ovary syndrome.
Description
Technical Field
The invention belongs to the technical field of microbial culture, relates to lactobacillus reuteri for improving polycystic ovary syndrome and application thereof, and in particular relates to lactobacillus reuteriLactobacillus reuteri LR38 strain, culture comprising the same, probiotic comprising the same, and use thereof in the manufacture of a medicament having a function of preventing, alleviating or treating polycystic ovary syndrome.
Background
Polycystic ovary syndrome (polycystic ovary syndrome, PCOS) is the most common metabolic disease of reproductive endocrine in women of childbearing age. Common clinical manifestations of PCOS include irregular menstruation, high androgen associated manifestations, infertility due to ovulation failure, etc., and may be accompanied by metabolic abnormality symptoms such as obesity, insulin resistance, hyperinsulinemia, glycolipid metabolic disorder, intestinal dysbacteriosis, etc. The long-term disease also can increase the incidence risk of diseases such as type II diabetes, cardiovascular and cerebrovascular diseases, metabolic syndrome, estrogen-related malignant tumor and the like, and seriously affect the fertility, long-term health and life quality of the diseased females.
Intestinal flora is an indispensable "microbial organ" of our body and plays a vital role in maintaining health. In recent years, the link between intestinal microbiota and metabolic diseases has been the focus of attention of researchers who have found a correlation between intestinal health and polycystic ovary syndrome, and thus suggest that there may be some mechanisms in the intestinal microbiota that affect polycystic ovary syndrome.
Therefore, how to provide a microbial preparation capable of effectively improving PCOS, relieving related metabolic level imbalance and abnormal secretion of sex hormone, a female patient can try to use medicines containing specific probiotics, and bad life experience brought by reproductive health problems caused by polycystic ovary syndrome to the patient is solved, so that new help can be provided for treating or assisting in treating PCOS based on intestinal flora as a target.
Disclosure of Invention
In view of the shortcomings of the prior art, the invention aims to provide a method for improving polycystic eggsLactobacillus reuteri of nest syndrome and application thereof, in particular to lactobacillus reuteriLactobacillus reuteri LR38 strain, culture comprising the same, probiotic comprising the same, and use thereof in the manufacture of a medicament having a function of preventing, alleviating or treating polycystic ovary syndrome.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a lactobacillus reuteri for improving polycystic ovary syndrome, said lactobacillus reuteri for improving polycystic ovary syndrome being designated lactobacillus reuteriLactobacillus reuteri LR38 strain (allo-synonym: lactobacillus reuteri)Limosilactobacillus reuteri) The preservation number is CGMCC No.24408, and the preservation date is 2022, 02 and 21.
The invention separates and stores a new strain of lactobacillus reuteri capable of improving polycystic ovary syndrome from healthy human breast milk samples in Suzhou city of Jiangsu province, and names the strain of lactobacillus reuteriLactobacillus reuteri LR38 strain, which is effective in ameliorating polycystic ovary syndrome and its associated metabolic disorder, symptoms of abnormal sex hormone levels, are embodied in: (1) Significantly improving ovarian tissue pathological symptoms of polycystic ovarian syndrome patients, including cystic follicles, corpus luteum quantity, testosterone level and the like; (2) Short chain fatty acid with rich antibacterial activity can be produced to participate in the immune reaction and endocrine regulation of the organism, so that the host metabolism level and sex hormone secretion are regulated; (3) can significantly improve the diversity of intestinal flora. Thus, the lactobacillus reuteriLactobacillus reuteri The LR38 strain can be used for preparing products (such as medicines and the like) for preventing, relieving or treating polycystic ovary syndrome.
In addition, lactobacillus reuteri is a probiotic, so that the lactobacillus reuteri LR38 obtained by screening is high in safety when being used in products (such as medicines and the like) for preventing, relieving or treating polycystic ovary syndrome; and the traditional Chinese medicine composition does not generate drug resistance, improves the occurrence of adverse reactions of physiological and psychological aspects and the like caused by the administration of antibiotics of the patients with the conventional polycystic ovary syndrome, and can be used for preventing, relieving or treating the products of the female polycystic ovary syndrome for a long time.
The screening steps of the lactobacillus reuteri related by the invention are as follows:
(1) Selecting a sample of healthy human breast milk from Suzhou city of Jiangsu province, performing 10-time gradient dilution with physiological saline with the mass concentration of 0.9%, diluting for 3 times, coating on a solid culture medium, culturing at 37 ℃ for 48 hours, picking up 3 bacterial colonies with different forms, marking and purifying on the surface of an improved MRS solid culture medium, picking up single bacterial colonies, performing expanded culture at 37 ℃ with a liquid culture medium, and preserving with glycerol with the mass concentration of 40%.
(2) And (3) carrying out in-vitro physiological characteristic test on the preserved 3 single strains, screening out a single strain with better gastric acid and bile salt resistance (artificial simulation) and SCFA (short chain fatty acid) yield, and identifying the single strain.
In a second aspect, the present invention provides a culture of lactobacillus reuteri for ameliorating polycystic ovary syndrome, the culture comprising: the Lactobacillus reuteri according to the first aspectLactobacillus reuteri The LR38 strain is inoculated in a culture medium at 30-38deg.C (such as 30deg.C, 32deg.C, 35deg.C, 36deg.C, 37deg.C, 38deg.C, etc.) and cultured for 18-24 h (such as 18 h, 19 h, 20 h, 21 h, 22 h, 23h, 24h, etc.), to obtain the final product.
Other specific point values within the above numerical ranges are all selectable, and will not be described in detail herein.
Preferably, the formulation of the culture medium comprises: peptone, beef extract, glucose, lactose, yeast extract, diammonium hydrogen citrate, K 2 PO 4 ·3H 2 O、MgSO 4 ·7H 2 O、MnSO 4 L-cysteine.
Specifically, the formula composition of the culture medium (liquid) comprises: 10g of peptone, 10g of beef extract, 20g of glucose, 10g of lactose, 5g of yeast extract, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2g、MgSO 4 ·7H 2 O 0.6g、MnSO 4 0.01g, L-cysteine 1g.
The invention has the advantages thatSelecting the above culture conditions, lactobacillus reuteriLactobacillus reuteri The LR38 strain can reach the growth stabilization period and has more excellent carbon source (glucose, fructose, lactose, galactose, maltose, sucrose, etc.) utilization ability.
In a third aspect, the present invention provides a probiotic with a method for preventing, alleviating or treating polycystic ovary syndrome, characterized in that the probiotic with a method for preventing, alleviating or treating polycystic ovary syndrome comprises lactobacillus reuteri according to the first aspectLactobacillus reuteri LR38 strain.
Lactobacillus reuteri according to the present inventionLactobacillus reuteri The LR38 strain can be used in related products alone or in combination with other strains.
Preferably, in the probiotic agent, the lactobacillus reuteriLactobacillus reuteri The number of viable bacteria of LR38 strain is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g, e.g. 1X 10 8 CFU/mL、2×10 8 CFU/mL、5×10 8 CFU/mL、8×10 8 CFU/mL、1×10 9 CFU/mL、5×10 9 CFU/mL、1×10 10 CFU/mL, etc., and other specific point values within the numerical range may be selected, and will not be described in detail herein.
Preferably, the formulation of the probiotic agent comprises freeze-dried powder, capsules, tablets or granules.
The probiotic agent can be freeze-dried powder, and the freeze-dried powder can be further prepared into capsules, tablets, granules, solutions and other dosage forms.
Preferably, the probiotic agent further comprises a protective agent and/or a co-additive.
Preferably, the protective agent comprises skim milk powder.
The auxiliary additive comprises any one or a combination of at least two of stachyose, fructooligosaccharide, galactooligosaccharide, mannooligosaccharide, trehalose, soybean oligosaccharide, resistant dextrin, xylooligosaccharide, polydextrose, alpha-lactalbumin or lactoferrin.
Further preferably, the probiotic agent further comprises lactobacillus acidophilusLactobacillus acidophilusLA88 strain; the lactobacillus acidophilusLactobacillus acidophilusThe preservation number of the LA88 strain is CGMCC No.24109 and 12 months and 15 days of 2021.
The invention also creatively discovers the lactobacillus reuteriLactobacillus reuteri LR38 strain capable of binding with Lactobacillus acidophilusLactobacillus acidophilusThe LA88 strain is compounded for use to prevent, relieve or treat polycystic ovary syndrome, has a remarkably excellent effect compared with a single microbial inoculum or other compound formulas, and shows that the LR38 strain and the LA88 strain have a synergistic effect in the aspects of regulating symptoms such as metabolic and sex hormone secretion abnormality of polycystic ovary syndrome patients, improving intestinal flora abundance of the patients and the like.
Preferably, the lactobacillus reuteriLactobacillus reuteri LR38 strain and lactobacillus acidophilusLactobacillus acidophilusThe ratio of the viable count of the LA88 strain to the viable count of (2-5): 1, such as 2:1, 3:1, 4:1, 5:1, etc., and other specific values within the numerical range can be selected, and will not be described in detail herein.
In the composite probiotic, the two strains have better synergistic effect when meeting the specific mass proportion relation.
In a fourth aspect, the present invention provides lactobacillus reuteri according to the first aspectLactobacillus reuteri Use of LR38 strain or the culture of the second aspect or the probiotic of the third aspect in the manufacture of a medicament having the function of preventing, alleviating or treating polycystic ovary syndrome.
Compared with the prior art, the invention has the following beneficial effects:
the invention separates and obtains and preserves a new strain of lactobacillus reuteri which can improve polycystic ovary syndrome and is named as lactobacillus reuteriLactobacillus reuteri LR38 strain, which is effective in ameliorating polycystic ovary syndrome and its associated metabolic disorder, symptoms of abnormal sex hormone levels, are embodied in: (1) Significantly improve polycysticOvarian tissue pathological symptoms of patients with ovarian syndrome, including cystic follicles, corpus luteum number, testosterone level and the like; (2) Short chain fatty acid with rich antibacterial activity can be produced to participate in the immune reaction and endocrine regulation of the organism, so that the host metabolism level and sex hormone secretion are regulated; (3) can significantly improve the diversity of intestinal flora. Thus, the lactobacillus reuteriLactobacillus reuteri The LR38 strain can be used for preparing products (such as medicines and the like) for preventing, improving or treating polycystic ovary syndrome.
The invention also creatively discovers the lactobacillus reuteriLactobacillus reuteri LR38 strain capable of binding with Lactobacillus acidophilusLactobacillus acidophilusThe LA88 strain is compounded for use to prevent, improve or treat female polycystic ovary syndrome, has a remarkably excellent effect compared with a single microbial inoculum or other compound formulas, and shows that the LR38 strain and the LA88 strain have a synergistic effect in the aspects of regulating symptoms such as metabolic and sex hormone secretion abnormality of patients with polycystic ovary syndrome, improving intestinal flora abundance of the patients and the like.
Drawings
FIG. 1 is a graph of the results of the detection of alpha diversity and differential flora by the intervention of Lactobacillus reuteri LR38 strain and/or Lactobacillus acidophilus LA88 strain.
Description of the embodiments
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The Lactobacillus reuteri is referred to in the followingLactobacillus reuteri The LR38 strain has a preservation unit of China general microbiological culture Collection center (CGMCC) No.24408, a preservation date of 2022, 02 and 21 days, and a preservation address of Beijing Chaoyang North Xiyu No. 1 and 3.
The Lactobacillus acidophilus is Lactobacillus acidophilusLactobacillus acidophilusLA88 strain, the preservation unit is China general microbiological culture Collection center,the preservation number is CGMCC No.24109, the preservation date is 2021, 12 and 15 days, and the preservation address is North Chen Silu No. 1 and No. 3 in the Chaoyang district of Beijing city.
Lactobacillus reuteri LR38 suspension referred to in the following: inoculating lactobacillus reuteri in MRS liquid culture medium, culturing at 37deg.C for 24 hr for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial liquid at 8000g for 10min, and collecting supernatant, and filtering with 0.22 μm sterile filter membrane to obtain lactobacillus reuteri supernatant; and (5) re-suspending the thalli by using PBS to obtain the microbial inoculum.
The lactobacillus acidophilus LA88 suspension referred to in the following: inoculating lactobacillus acidophilus LA88 into MRS liquid culture medium, culturing at 37deg.C for 24 hr for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial solution at 8000g for 10min, collecting supernatant, and filtering with 0.22 μm aseptic filter membrane to obtain Lactobacillus acidophilusSupernatant; and (5) re-suspending the thalli by using PBS to obtain the microbial inoculum.
The formulation composition of the MRS medium involved in the following includes: 10g of peptone, 10g of beef extract, 20g of glucose, 10g of lactose, 5g of yeast extract, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2g、MgSO 4 ·7H 2 O 0.6g、MnSO 4 0.01g, L-cysteine 1g.
Examples
In this example, a strain of lactobacillus reuteri for improving polycystic ovary syndrome was selected as follows:
(1) Selecting a sample of healthy human breast milk from Suzhou city of Jiangsu province, performing 10-time gradient dilution with physiological saline with the mass concentration of 0.9%, diluting for 3 times, coating on a solid culture medium, culturing at 37 ℃ for 48 hours, picking out bacterial colonies with different forms, performing streak purification on the surface of the MRS solid culture medium, picking out single colonies, performing expansion culture at 37 ℃ with a liquid culture medium, and preserving with glycerol with the mass concentration of 35%.
(2) In vitro physiological property tests are carried out on the preserved single bacteria, and the method is specifically as follows:
(2.1) acid and bile salt resistance test:
the main reagents are pepsin, trypsin, sodium taurocholate and CaCO 3 Etc. Adjusting pH of MRS culture medium to 3.0, sterilizing at 121deg.C for 15min, inoculating 2% inoculum size into activated two-generation liquid culture medium, culturing at 37deg.C for 24 hr, and measuring its absorbance change (OD) during 24 hr 600 A value; adding 0.1% ox gall salt into MRS culture medium, sterilizing at 121deg.C for 15min, inoculating 2% inoculum size into activated two-generation liquid culture, culturing at 37deg.C for 24 hr, and measuring its absorbance change or OD during 24 hr 600 Value, finally select two fates OD 600 The next experiment was performed with 10 strains of relatively large value.
Acid resistance experiment: based on PBS buffer solution with pH=6.8, the pH value is adjusted to 3.0 by using 37% hydrochloric acid, the mixture is sterilized at 121 ℃ for 15min, then the activated two-generation liquid culture is inoculated according to 10% inoculum size, the culture is cultured at 37 ℃, and the sampling and the determination of the viable count are respectively carried out at 0min, 30min, 60min, 90min and 120 min.
Bile salt resistance experiment: the liquid culture after two generations of strain activation is inoculated into MRS culture media (0.1%, 0.2%, 0.3%, 0.5% and 2% of bile salts in the culture media) containing different bile salt concentrations in an inoculation amount of 2%, meanwhile, MRS culture media without bile salts are used as a control, the culture media are cultivated for 24 hours at the constant temperature of 37 ℃ and then sampled to determine the number of viable bacteria, and the superior strain with acid resistance and bile salt resistance is screened by combining the last experimental result.
(2.2) acid generating ability test:
the acid producing capacity of the strain was determined by titration. The strain preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to 2% of inoculum size after being activated, the culture is carried out for 24 hours at the constant temperature of 37 ℃, 10mL of fermentation liquor of each strain is taken in 50mL of sterile water, 2-3 drops of phenolphthalein with the concentration of 1g/L are dripped as an indicator, and 0.1mol/L NaOH standard solution is used for titration, and each sample is parallel for 3 times when pink solution appears and does not fade after 30 seconds. The calculation formula of the blank control is that the unvaccinated MRS liquid culture medium is:total acidity/(g.L) -1 ) = (V1-V2) ×c×100×V0 -1 (V1 is the volume of NaOH solution consumed by the sample, mL, V2 is the volume of NaOH solution consumed by the blank, mL, V0 is the total volume of the diluent, mL, and c is the concentration of standard NaOH, mol/L).
By combining the screening experiments, a strain with the strongest acid production capacity, gastric acid and bile salt tolerance is selected.
Examples
In this example, the strains obtained by screening in example 1 were subjected to morphological identification and 16S rRNA molecular biology identification, as follows:
(1) Morphological identification:
the strain was inoculated in MRS solid medium, cultured at 37℃for 48 hours, and then observed under a microscope. The colonies were observed to be milky white and full dots. The strain in the logarithmic growth phase is selected, and is detected by an optical microscope, and is observed by microscopic examination after smear and gram staining: gram staining is positive, the strain is in a rod shape, and no spore or flagellum exists.
(2) 16S rRNA molecular biology identification:
taking out the strain preserved at-80 deg.C, inoculating into a centrifuge tube filled with 20mL MRS liquid culture medium according to 2% ratio, culturing at 37 deg.C for 24 hr, centrifuging at 6000 rpm for 10min, removing supernatant, and collecting thallus. Extracting genome of the strain, adding bacterial universal primer for PCR amplification, and delivering amplified product to Shanghai biological engineering Co., ltd for sequencing identification. The strain is subjected to sequencing analysis, and the 16S rDNA sequence of the strain is shown as SEQ ID No. 1. The sequences obtained by sequencing were subjected to nucleic acid sequence alignment in GeneBank, and the results show that the strain is Lactobacillus reuteri.
SEQ ID No:1：
ATACATGCAGTCGTACGCACTGGCCCAACTGATTGATGGTGCTTGCACCTGATTGACGATGGATCACCAGTGAGTGGGGACGGGTGAGTAACACGTAGGTAACCTGCCCCGGAGCGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAACAACAAAAGCCACATGGCTTTTGTTTGAAAGATGGCTTTGGCTATCACTCTGGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTGGAGAAGAACGTGCGTGAGAGTAACTGTTCACGCAGTGACGGTATCCAACCAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTGCTTAGGTCTGATGTGAAAGCCTTCGGCTTAACCGAAGAAGTGCATCGGAAACCGGGCGACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGOCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATCTTGCGCTAACCTTAGAGATAAGGCGTTCCCTTCGGGGACGCAATGACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTACTAGTTGCCAGCATTAAGTTGGGCACTCTAGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGACGACGTCAGATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGTCGCAAGCTCGCGAGAGTAAGCTAATCTCTTAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTTGTAACGCCCAAAGTCGGTGGCCTAACCATTATGGAGGGAGCCGCCTAAGGCGGGACAGATGACTGGGGTGAGTCGTACAAG。
Based on the results of the 16S rRNA molecular biological identification and morphological identification of example 2, it was confirmed that the strain belongs to Lactobacillus reuteri, designated Lactobacillus reuteriLactobacillus reuteri LR38 strain.
Examples
In this example, lactobacillus reuteri was treatedLactobacillus reuteri Culture conditions of LR38 strain were optimized as follows:
inoculating Lactobacillus reuteri LR38 into MRS liquid culture medium, respectively culturing at different temperatures of 10-50deg.C for 48h, and measuring OD of the culture solution by enzyme-labeled instrument at intervals 600 Numerical values. The results are shown in Table 1:
TABLE 1
The result shows that LR38 can reach the growth stabilization period after 20-24 hours of culture at 35-38 ℃.
The carbon source utilization capacity of the test strain LR38 was determined by performing a sugar fermentation reaction on the test strain LR38 using an API 50CHL medium (basal medium consisting of API 50CH test strips of 48 fermentable carbohydrates) and an API 50CH test strip according to API bacterial identification criteria. The principle of the method is that the strain to be measured is used for preparing suspension, the suspension is inoculated in each test strip small tube, and after the culture, the carbon source tube which can be utilized can produce acid due to fermentation, and the pH value is reduced, so that the indicator changes color.
As a result, strain LR38 can use various sugar sources such as glucose, fructose, lactose, galactose, maltose, sucrose and the like as carbon sources.
Examples
This example demonstrates lactobacillus reuteriLactobacillus reuteri The LR38 strain has gastric acid and bile salt resistance, and comprises the following steps:
(1) Preparing artificial gastric juice and bile salt:
the artificial gastric juice contains 0.20% of NaCl and 0.30% of pepsin by mass fraction, the pH is respectively regulated to 2.0, 2.5 and 3.0 by using HCl, and the artificial gastric juice is filtered and sterilized for standby.
10% ox gall salt: 10.0g of ox gall salt (Walker, national pharmaceutical group chemical reagent Co., ltd., shanghai, china) was weighed into 100mL of sterile water, and was sterilized by filtration through a 0.22 μm filter membrane.
MRS medium containing 0.1% bile salts: MRS medium (Beijing Soy Co., ltd.) was prepared according to the instructions, and after high-pressure steam sterilization (121 ℃ C., 15 min), a proper amount of 10% ox gall salt solution was added to a final concentration of 0.1%.
(2) Gastric acid resistance test:
1.0. 1.0 mL Lactobacillus reuteri LR38 suspension (1×10 concentration) 9 CFU/mL, measuring bacterial liquid concentration by the method of national standard "GB 4789.35-2016 food safety national Standard food microbiology detection lactic acid bacteria detection", mixing with 9.0 mL of artificial gastric juice with pH of 2.0, 2.5 and 3.0, respectively, anaerobic stationary culturing at 37deg.C, sampling after starting (0 h) and processing 3h, respectively3 parallels were made. The viable count was determined by pour culture and the viability was calculated as follows:
survival (%) =n1/n0×100%,
wherein, N1: viable count after 3 hours of artificial gastric juice treatment; n0: viable count of 0 h. The test results are shown in Table 2.
TABLE 2
(3) Bile salt resistance test:
1.0. 1.0 mL Lactobacillus reuteri LR38 suspension (1×10 concentration) 9 CFU/mL, the concentration of bacterial liquid is measured by the method in national standard food safety national standard food microbiology detection lactic acid bacteria detection, GB 4789.35-2016), mixed with 9.0 mL of a bovine bile salt MRS culture medium containing 0.1%, and subjected to anaerobic stationary culture at 37 ℃, sampling is carried out after the beginning (0 h) and the treatment of 3h respectively, the viable count is measured by a pouring culture method, and the survival rate is calculated according to the following formula:
survival (%) =n1/n0×100%,
wherein, N1: viable count after bile salt treatment for 3 hours; n0: viable count of 0 h. The test results are shown in Table 3.
TABLE 3 Table 3
As can be seen from table 2 and table 3, lactobacillus reuteri LR38 of the present invention has good gastric acid resistance, and the survival rate can reach 78.3% when incubated for 3 hours in artificial gastric juice with pH of 2.0; incubating in artificial gastric juice with pH of 2.5 for 3 hours, wherein the survival rate can reach 90.4%; incubation for 3h in artificial gastric juice with pH of 3.0, the survival rate can reach 94.7%. The good gastric acid and bile salt tolerance creates conditions for the field planting of the compound in the gastrointestinal tract, improving the metabolism of the organism and the hormone secretion level, and preparing the product for preventing, improving or treating the polycystic ovary syndrome.
Examples
Lactobacillus reuteriLactobacillus reuteri Safety in use test of LR38 strain:
according to the 2010 edition Chinese pharmacopoeia, 6 SPF-grade mice (weight about 20-25 g) were selected, and the mice were cultured by intraperitoneal injection of 0.6. 0.6 mL fresh MRS medium to obtain LR38 culture solution (viable count about 2×10) 9 CFU/mouse) and the change in body weight of each mouse was measured daily, and physiological changes such as mental state, behavioral activity, etc. before and after injection were recorded. As a result, the weight of the mice is slightly increased within one week, no obvious poisoning symptoms occur, the behavior is normal, no death phenomenon and no adverse reaction occur, so that the lactobacillus reuteri LR38 is considered to be high in safety and belongs to normal non-toxic probiotics.
Examples
This example demonstrates lactobacillus reuteriLactobacillus reuteri LR38 strain relieves the effects of symptoms of polycystic ovary syndrome in rats as follows:
female SD (Sprague-Dawley) rats at 8 weeks of age were purchased from Shanghai laboratory animal center and have been approved by ethical Committee for Shanghai laboratory animal research center (ethical number: 2022032003). All animals were kept under specific pathogen-free barrier conditions, alternately cycled 12 hours light and 12 hours dark and provided feed and water. Animal experiments strictly follow the national institutes of health, guidelines for laboratory animal care and use.
(1) Establishment of polycystic ovary syndrome rat model: according to the methods commonly used in the art (ref: wang MX, yin Q, xu X. A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet).Med Sci Monit2020 May 25;26:e922136 DOI 10.12659/MSM.922136.) the use of letrozole (available from Jiangsu Hengrui medicine Co., ltd.) induces polycystic ovary syndrome in rats. The 48 rats were randomly divided into 6 groups: control group (CTL), untreated polycystic ovary syndrome model group (MC), polycystic ovary syndrome group treated with lactobacillus reuteri LR38 (LR 38), polycystic ovary syndrome group treated with lactobacillus acidophilus LA88 (LA 88), lactobacillus reuteri LR38 andpolycystic ovary syndrome group treated with lactobacillus acidophilus LA88 (lr38+la 88, viable count ratio 3:1), polycystic ovary syndrome group treated with lactobacillus reuteri ATCC53608 and lactobacillus acidophilus LA88 (ATCC 53608+la88, viable count ratio 3:1). The intervention of each group of microbial agents is 4 multiplied by 10 9 CFU/day, 1 week adaptation period was performed prior to dosing. To evaluate the effect of probiotics on polycystic ovary syndrome, we induced polycystic ovary syndrome symptoms with letrozole (1 mg/kg,1% carboxymethyl cellulose lavage) for 21 consecutive days, CTL rats lavaged with 1% carboxymethyl cellulose instead of letrozole. All rats were fed normal diet for 28 consecutive days, and body weight (results shown in Table 4, units: g) and diet consumption were recorded every 3 days.
(2) Inoculating the strains into MRS liquid culture medium respectively, culturing at 37deg.C for 24-h for activation, and activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial liquid at 6000 g for 10min, collecting supernatant, and filtering with 0.22 μm sterile filter membrane to obtain supernatant; the cells were resuspended in PBS to obtain each bacterial suspension.
(3) Serum analysis: rats were fasted at night and sacrificed on day 29. Blood samples were collected, stored at 20 ℃ for 1 hour, and then centrifuged at 3000 g for 15min to obtain serum.
Determination of metabolic levels: total Cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) were measured using a biochemical analyzer (Beckman Coulter, calif.) (the results are shown in Table 5).
Determination of sex hormone levels: testosterone, luteinizing Hormone (LH), estradiol (E2), progesterone, anti-mullerian hormone (AMH), gonadotropin releasing hormone (GnRH) were measured using an enzyme-linked immunosorbent assay kit according to the manufacturer's protocol (wuhan purity biotechnology company) (results shown in table 6).
(4) Oral Glucose Tolerance Test (OGTT): rats were fasted at night and were tested for oral glucose tolerance on day 26. After baseline testing, rats were perfused with gastric glucose (2.5 g/kg body weight, 50% dextrose solution). Blood glucose concentrations of 30, 60, 90 and 120min after administration were measured by tail vein blood sampling (results shown in Table 7, units: mmol/L) using blood glucose test paper (trade name: excellent Jin Rui blood glucose test paper, roche).
(5) Fecal sampling and short chain fatty acid detection: the colon of the mice was collected and the feces were rapidly frozen in sterile tubes for storage at-80 ℃. The short chain fatty acid content was analyzed using gas chromatography-mass spectrometry and total SCFAs levels in ileal content, cecal content, colonic content and faeces were measured (results shown in Table 8, units/. Mu.mol/g).
TABLE 4 Table 4
As can be seen from table 4, rats in the MC group grew rapidly and grew faster after 4 weeks of intervention compared to the CTL group. In the pre-probiotic intervention group, the weight growth trend of rats in the LR38 group is slowed down, and the overall growth speed is reduced compared with that of rats in the MC group; in addition, it was unexpectedly found that the weight loss effect was more pronounced in rats of the lr38+la88 group when the lactobacillus reuteri and lactobacillus acidophilus were combined for intervention, especially at week 4, the average body weight tended to approach that of the CTL group.
TABLE 5
As can be seen from Table 5, the Triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels were higher in the MC group and the Total Cholesterol (TC) and high density lipoprotein cholesterol (HDL-C) levels were reduced in the contrast CTL group, indicating that letrozole successfully induced metabolic disorders in rats. However, when probiotics intervened, we found that LR38 group rats had decreased TG and LDL-C levels and recovered TC and HDL-C levels. In addition, we have unexpectedly found that in the LR38+LA88 group, the serum TC, HDL-C, TG, LDL-C levels in rats were substantially restored to normal levels, and the animals tended to become CTL groups. Overall, lactobacillus reuteri LR38 had excellent effect of improving symptoms of metabolic disorder in polycystic ovary syndrome rats.
TABLE 6
The data in table 6 reflect the endocrine status of the experimental rats. By analyzing the concentration of serum sex hormone, we find that the levels of testosterone, LH and GnRH of MC rats are obviously higher, the symptoms of polycystic ovary syndrome are presented, and meanwhile, the levels of progesterone, E2 and AMH are lower, so that the abnormal ovarian function of the MC rats is reflected. However, the level of androgenic testosterone in LR38 rats showed a trend to decrease and the level of estrogens increased with the intervention of probiotics, i.e. the symptoms of polycystic ovary syndrome were improved. In addition, we find that the compound probiotics group LR38+LA88 has more obvious effect of restoring the estrogen level of the experimental rats, so that the symptoms related to polycystic ovary syndrome are relieved.
TABLE 7
Table 7 reflects the change of blood glucose concentration of experimental rats in 2 hours, compared with the CTL group, the MC rats can not normally regulate blood glucose concentration due to the fact that the regulation and control of blood glucose metabolism of the MC rats are blocked, but in the LR38 rats, the blood glucose metabolism capacity is improved, and the normal blood glucose metabolism can be basically recovered, especially when LR38+LA88 is combined, the effect on regulation and control of blood glucose metabolism of the model rats is more obvious.
TABLE 8
As can be seen from the results in Table 8, compared with the CTL group, the MC group rat intestinal flora metabolite has reduced total SCFAs in cecum, colon and feces, i.e. polycystic ovary syndrome affects intestinal flora steady state to reduce SCFAs content, and thus metabolic disorders such as insulin resistance may be induced, and the experimental rats presented in Table 8 have impaired blood glucose regulation. However, under the intervention of probiotics, the detected quantity of short chain fatty acid in the intestinal tract and the excrement of the rats tested in the LR38 group is obviously increased, that is, the intervention of lactobacillus reuteri can improve the problem of dysbacteriosis of intestinal tract of polycystic ovary syndrome, and the content of SCFAs is increased, thereby being beneficial to the energy intake of organisms, the regulation of immunity, the improvement of metabolic level and the like. In addition, we found that this effect was more pronounced when LR38 and LA88 were combined.
Examples
This example demonstrates lactobacillus reuteriLactobacillus reuteri Effects of LR38 strain on rat ovarian tissue pathology:
(1) The PCOS rat model was constructed as described in example 5.
(2) Rat ovarian tissue pathology analysis:
immediately after euthanasia of the experimental rats, ovarian and colon samples were taken from CTL, MC, LR38 and lr38+la88 groups and fixed with 4% paraformaldehyde. Hematoxylin-eosin (HE) staining and immunohistochemistry were performed. In the literature (Wang MX, yin Q, xu X. A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet).Med Sci Monit2020 May 25;26:e922136) determination of morphology: the granulosa cell layer becomes weak and the follicle with the membrane cell layer thickened is considered to be a cystic follicle. At the same time, the number of vesicles, vesicle duty ratio (vesicle duty ratio=number of vesicles/total number of vesicles), and corpus luteum were calculated. The results are shown in Table 9.
TABLE 9
In a normal letrozole-induced polycystic ovary syndrome rat model, the pathological state of the ovary is mainly caused by the disturbance of sex hormone level, and the ovary presents symptoms such as luteal phase reduction, polycystic vesicles and the like. Compared with the CTL group, the number of cystic follicles of the rats in the MC group is obviously increased along with the rapid decrease of the corpus luteum number, the thickness of the cell layers is thinned, but the probiotic dry prognosis, the LR38 group rats can effectively reduce the weight index of the ovaries and the number of the cystic follicles of the rats, and simultaneously partially restore the corpus luteum number of the ovaries. In addition, we have unexpectedly found that the ovary morphology of the LR08+LA88 combined rat is basically recovered to be normal, the corpus luteum is rich, the follicles are more, and the mice basically tend to be in CTL groups. In other words, lactobacillus reuteri LR38 is able to restore morphological abnormalities of the ovaries by modulating sex hormone levels.
Examples
This example demonstrates that lactobacillus reuteri LR38 regulates intestinal flora function as follows:
(1) The PCOS rat model was constructed as described in example 5.
(2) Intestinal flora analysis: feces were collected from rats in CTL, MC, LR38 and lr38+la88 groups. Total DNA was extracted from 200mg of stool using QIAamp stool DNA extraction kit (Qiagen). The 16S rRNA V3-V4 region was PCR amplified using 341F (SEQ ID No: 2:5 '-CCTACGGGNGGCWGCAG-3') and 805R (SEQ ID No: 3:5 '-GACTACHVGGGTATCTAATCC-3') primers. The final 16S rRNA gene amplicon library was sequenced on the MiSeq platform (Illumina) using the 2 x 300 bp paired-end protocol. The following analysis was performed using Usearch11 to combine paired end reads obtained and retain reads of length ≡400 pb. All mass filter sequences were mapped to ASVs without chimeras and ASV abundance tables were created using userch 11 with default settings. The 16S rRNA database of RDP training set (v 18 version) was used as the reference database. Based on ASVs abundance tables, index of Chao1 and Shannon diversity (alpha diversity) was calculated using userch, intervention effects were determined by one-way analysis of variance (ANOVA), and differences between groups were analyzed post-hoc by Tukey test significance difference test. The results of the lactobacillus reuteri LR38 intervention on alpha diversity detection are shown in figure 1.
As can be seen from fig. 1, the microbial community α diversity was significantly reduced in the MC group rats compared to the CLT group. Specifically, the microbial abundance decreases (expressed as the Chao1 index), and the microbial diversity decreases (expressed as the Shannon index). Comparison of LR38 group with MC group shows that LR38 increases α diversity of the microbiota and that the probiotic composite formulation has more pronounced effect on improving intestinal flora diversity in polycystic ovary syndrome rats when lactobacillus reuteri LR38 and lactobacillus acidophilus LR88 co-act.
The applicant states that the present invention is illustrated by the above examples as a lactobacillus reuteri for improving polycystic ovary syndrome and its use, but the present invention is not limited to, i.e., it is not meant that the present invention must be practiced in dependence upon the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. The lactobacillus reuteri for improving polycystic ovary syndrome is characterized by being named as lactobacillus reuteri @, wherein the lactobacillus reuteri for improving polycystic ovary syndrome is a compound of the formulaLactobacillus reuteri) LR38 strain with preservation number of CGMCC No.24408 and preservation date of 2022, 02 and 21.
2. A culture of lactobacillus reuteri for ameliorating polycystic ovary syndrome, the method of preparing the culture comprising: the lactobacillus reuteri of claim 1Lactobacillus reuteri) Inoculating LR38 strain into culture medium, and culturing at 30-38deg.C for 18-24 h.
3. A first partA probiotic for preventing, alleviating or treating polycystic ovary syndrome, comprising Lactobacillus reuteri of claim 1Lactobacillus reuteri) LR38 strain.
4. The probiotic agent for preventing, alleviating or treating polycystic ovary syndrome of claim 3, wherein said lactobacillus reuteri is selected from the group consisting ofLactobacillus reuteri) The number of viable bacteria of LR38 strain is not less than 1×10 8 CFU/mL or 1X 10 8 CFU/g。
5. The probiotic having the effect of preventing, alleviating or treating polycystic ovary syndrome of claim 3, wherein said probiotic is in a dosage form comprising lyophilized powder, capsule, tablet or granule.
6. A probiotic with a prevention, alleviation or treatment of polycystic ovary syndrome according to claim 3, characterized in that said probiotic further comprises a protective agent and/or an auxiliary additive.
7. The probiotic with a prevention, alleviation or treatment of polycystic ovary syndrome of claim 6, wherein said protective agent comprises skim milk powder;
the auxiliary additive comprises any one or a combination of at least two of stachyose, fructooligosaccharide, galactooligosaccharide, mannooligosaccharide, trehalose, soybean oligosaccharide, resistant dextrin, xylooligosaccharide, polydextrose, alpha-lactalbumin or lactoferrin.
8. The probiotic agent for preventing, alleviating or treating polycystic ovary syndrome of claim 3, further comprising lactobacillus acidophilusLactobacillus acidophilus) LA88 strain; the lactobacillus acidophilus isLactobacillus acidophilus) Preservation code of LA88 strainThe number is CGMCC No.24109, and the year of 2021 is 12 and 15.
9. The probiotic agent for preventing, alleviating or treating polycystic ovary syndrome of claim 8, wherein said lactobacillus reuteri @ is @Lactobacillus reuteri) LR38 strain and lactobacillus acidophilusLactobacillus acidophilus) The ratio of the viable count of the LA88 strain was (2-5): 1.
10. Lactobacillus reuteri according to claim 1Lactobacillus reuteri) Use of LR38 strain or the culture of claim 2 or the probiotic of any one of claims 3-9 in the manufacture of a medicament having the function of preventing, alleviating or treating polycystic ovary syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310399703.5A CN116445346B (en) | 2023-04-14 | 2023-04-14 | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310399703.5A CN116445346B (en) | 2023-04-14 | 2023-04-14 | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116445346A CN116445346A (en) | 2023-07-18 |
| CN116445346B true CN116445346B (en) | 2023-10-13 |
Family
ID=87119712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310399703.5A Active CN116445346B (en) | 2023-04-14 | 2023-04-14 | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116445346B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115364126B (en) * | 2021-05-17 | 2023-11-21 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of polycystic ovary syndrome treatment drug |
| CN117305188B (en) * | 2023-11-27 | 2024-02-13 | 山东中微众康生物科技有限公司 | Lactobacillus acidophilus RZKLa0701 capable of promoting bone growth of children and application thereof |
| CN117844714B (en) * | 2024-03-04 | 2024-05-17 | 微康益生菌(苏州)股份有限公司 | Probiotics for regulating and controlling brain-derived neurotrophic factors and sex hormones and application thereof |
| CN118667725B (en) * | 2024-08-22 | 2024-12-06 | 中国农业科学院北京畜牧兽医研究所 | Probiotic compound agent for improving fertility of female animals and application |
| CN119265084B (en) * | 2024-12-03 | 2025-02-18 | 山东环亿生物科技有限公司 | Lactobacillus reuteri A-1 and application thereof in preparation of iron supplementing and intestinal tract regulating products |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470008A (en) * | 2022-01-26 | 2022-05-13 | 佛山市第一人民医院 | Application of lactobacillus brevis or lactobacillus reuteri in preparation of product for treating premature ovarian failure |
| EP4000626A1 (en) * | 2020-11-16 | 2022-05-25 | concrete flowers GmbH | Pharmaceutical preparation |
| WO2022133198A1 (en) * | 2020-12-18 | 2022-06-23 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
-
2023
- 2023-04-14 CN CN202310399703.5A patent/CN116445346B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4000626A1 (en) * | 2020-11-16 | 2022-05-25 | concrete flowers GmbH | Pharmaceutical preparation |
| WO2022133198A1 (en) * | 2020-12-18 | 2022-06-23 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| CN115364126A (en) * | 2021-05-17 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome |
| CN114470008A (en) * | 2022-01-26 | 2022-05-13 | 佛山市第一人民医院 | Application of lactobacillus brevis or lactobacillus reuteri in preparation of product for treating premature ovarian failure |
Non-Patent Citations (4)
| Title |
|---|
| Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota;Yufeng He et al.;《Food Funct.》;第11卷;5192-5204 * |
| Probiotics supplementation for management of type II diabetes risk factors in adults with polycystic ovarian syndrome: a meta-analysis of randomized clinical trial;Chengcheng Zhang et al.;《ElsevierFood Science and Human Wellness》;第12卷;1053-1063 * |
| 基于肠道菌群探讨中医药干预多囊卵巢综合征;林倍倍等;《中医学报》;第36卷(第1期);89-93 * |
| 肠道菌群与多囊卵巢综合征发病关系的研究进展;徐洁颖等;《上海交通大学学报（医学版）》;第36卷(第8期);1250-1255 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116445346A (en) | 2023-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116445346B (en) | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof | |
| US11260082B2 (en) | Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN116590181B (en) | Lactobacillus paracasei for improving inflammatory reaction caused by microplastic pollution and application thereof | |
| CN116688019A (en) | Litchi fermentation product for improving fecal occult blood and intestinal barrier and regulating intestinal flora | |
| JP4540376B2 (en) | Lactic acid bacteria production substances | |
| CN109983115B (en) | Lactobacillus gasseri and culture method and application thereof | |
| US10799540B2 (en) | Faecalibacterium longum and application thereof | |
| CN113797232A (en) | Composition with function of relieving insulin resistance and application thereof | |
| CN113388554A (en) | Lactobacillus plantarum SHY130 and application thereof in relieving diabetes | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN117965341B (en) | A strain of Lactobacillus plantarum FLP-215 and its application in ulcerative colitis, diabetes and organ damage | |
| CN113215020A (en) | Roseburia MGB-2 and application thereof | |
| CN118440868A (en) | Lactobacillus plantarum and application thereof | |
| CN118240686A (en) | A fermented lactobacillus XY18 for relieving colitis and its application | |
| CN109874329B (en) | Fusarium butyricum and culture method and application thereof | |
| CN117224580A (en) | Application of Wittman coagulans in preparation of 1-deoxynojirimycin and medicines for improving abnormal metabolism of organism glycolipid | |
| CN116478874A (en) | Lactobacillus paracasei for improving chronic low-grade inflammation and application thereof | |
| CN116987617A (en) | Lactobacillus rhamnosus UA260 strain and application thereof in blood uric acid regulation | |
| WO2018107364A1 (en) | Collinsella shenzhenensis and applications thereof | |
| CN114617265A (en) | Application of inactivated lactobacillus casei IOB-P9 metagenesis powder in reducing blood sugar | |
| CN118028190B (en) | Lactobacillus mucilaginosus BAS313 and application thereof in preparation of hypoglycemic products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |